Life Biosciences’ Post

Learn more about INIA Bioscience's vision of making biologics obsolete in the treatment of psoriasis, providing patients with a superior, side-effect-free alternative. Watch the video here: https://lnkd.in/et3aqUBM

Learn more about INIA Bioscience's vision of making biologics obsolete in the treatment of psoriasis, providing patients with a superior, side-effect-free alternative. Watch the video here: https://lnkd.in/ez7rqXv7

Join Charnwood Discovery and Gyros Protein Technologies for an on-demand webinar with Dr James Krupa. Explore the complexities of cyclic peptide synthesis, including their growing prominence in drug development, synthesis challenges, and solutions. Key insights include: ➡ Synthesis and cyclization of peptides ➡ Managing issues like ring strain and instability ➡ Understanding structure–activity relationships (SAR) in drug discovery Download the on-demand webinar here: https://lnkd.in/eYVPa8up #CyclicPeptides #DrugDiscovery #PeptideSynthesis #Biotech #Webinar

Thanks to Imran Ahson MD, DMD for the stimulating conversation in his video podcast. We discussed #biotech and #pharmaceutical advances–past, present and future–plus some reflections on drugs for #longevity, #career choices, the potential of #AI in drug development, #drug pricing and the US #healthcare system.

🔬 Curious about the current state of the biotech market? 📈 Wondering how investor sentiment is evolving and what factors are influencing investment decisions? 🌍 Interested in understanding the geopolitical and economic factors impacting the global biotech landscape? These are the questions I frequently get asked by clients across the biopharma sector. As part of the LifeSci Partners platform, I'm fortunate to have access to a wealth of knowledge and insights from colleagues who closely monitor market dynamics, enabling us to provide informed guidance to biopharma companies. 🎯 For those seeking a regular, thorough, and insightful overview of the biotech market, I highly recommend tuning into LifeSci Capital LLC's monthly Biotech Capital Markets Update. This interactive discussion delves into the current state of the biotechnology markets, offering valuable insights on financing dynamics within the healthcare sector. #biotech #capitalmarkets #lifesciences #marketintelligence #healthcarefinance

Are you developing new drugs for the hot target #GLP1R? Then listen up drug discovery experts! We are very excited to announce a significant breakthrough at Cube Biotech! Leveraging our 𝐍𝐚𝐭𝐢𝐯𝐞𝐌𝐏™ 𝐩𝐥𝐚𝐭𝐟𝐨𝐫𝐦 to stabilize human GLP1R, we have successfully obtained novel small molecule binders by using an AS-MS screening approach with our collaboration partner Momentum Biotechnologies. Our highly thermal-stable, full-length, wild-type, human GLP1R available in our 𝐍𝐚𝐭𝐢𝐯𝐞𝐌𝐏™ 𝐩𝐥𝐚𝐭𝐟𝐨𝐫𝐦 is easy to handle for #DrugDiscovery screenings with superior results in shorter lead times. Stay tuned for the upcoming launch on our web page. Get ready to explore hot membrane protein targets in our 𝐍𝐚𝐭𝐢𝐯𝐞𝐌𝐏™ 𝐩𝐥𝐚𝐭𝐟𝐨𝐫𝐦 to revolutionize your research and drug discovery efforts! Is your target not in our Drug Discovery Pipeline? Interested in learning more about our 𝐍𝐚𝐭𝐢𝐯𝐞𝐌𝐏™ 𝐩𝐥𝐚𝐭𝐟𝐨𝐫𝐦 for stabilization of any #MembraneProtein? 𝐓𝐡𝐞 𝐆𝐚𝐦𝐞 𝐢𝐬 𝐨𝐧: 𝐂𝐡𝐚𝐥𝐥𝐞𝐧𝐠𝐞 𝐮𝐬 𝐰𝐢𝐭𝐡 𝐲𝐨𝐮𝐫 𝐦𝐨𝐬𝐭 𝐜𝐨𝐦𝐩𝐥𝐞𝐱 𝐭𝐚𝐫𝐠𝐞𝐭𝐬! Book a meeting with me to discuss your project: https://lnkd.in/dNmvA45r #MembraneProteins #DrugDiscovery #AffinitySelectionMassSpectrometry #GLP1R #CubeBiotech 

🔬 Exciting Breakthrough in Biotech! Tierra Biosciences has just announced the successful closure of their $11.4M Series A funding round, led by Material Impact with contributions from notable investors like Prosus Ventures, In-Q-Tel, Hillspire, Freeflow Ventures, Creative Ventures, and Social Capital. This significant investment marks a milestone in the advancement of protein synthesis technology. Tierra Biosciences, renowned for its pioneering cell-free protein production platform, is revolutionizing the way we approach protein engineering. By leveraging predictive AI and high-throughput technology, they provide rapid access to custom proteins, accelerating discovery and development processes in various industries, including pharmaceuticals, agriculture, and more. Their innovative approach, which combines the power of AI language models with high-throughput cell-free platforms, is pushing the boundaries of protein engineering. Tierra’s technology is not just enhancing protein synthesis; it’s reshaping entire industries and promising a new era of bioeconomy innovation. With this new funding, Tierra Biosciences is set to expand its reach and continue its mission to democratize access to engineered proteins, driving significant advancements in human health, environmental sustainability, and global food security. A big congratulations to the Tierra team on this achievement! #seriesa #biotech #venturecapital

Congratulations to Nuclera on securing $75 million in Series C financing! Nuclera, the Amadeus-backed biotechnology company revolutionising protein expression and purification workflows with its eProtein Discovery™ benchtop system, has successfully closed a $75 million financing round. This significant investment, led by Elevage Medical Technologies and supported by Patient Square Capital, British Patient Capital, and others, will accelerate the commercialization of Nuclera’s innovative platform. Dr. Michael Chen, CEO and co-founder of Nuclera, shared: “This funding will accelerate our mission to provide ready-to-use benchtop protein screening and making tools to empower protein scientists around the world. We are excited to enhance our support for our customers, enabling them to make proteins for drug discovery more efficiently and effectively for many years to come.” Dr. Michael Wasserman, COO of Elevage Medical Technologies, added: “Nuclera has developed a solution for one of the leading obstacles in drug discovery: access to proteins that are needed throughout the drug discovery process. Elevage is proud to support Nuclera and its leadership team as it continues to bring the eProtein Discovery System to drug discovery researchers across the globe.” 🔗Read the full release here: https://bit.ly/48b0bQX #Nuclera #SeriesC #biotech #proteinexpression #drugdiscovery

Working with patient-derived cells. In the latest instalment of their three-part video series, we hear from the Inaphaea BioLabs team and collaborators as they speak about how they work with PDCs. #Assays #AssayDevelopment #BioTech #DrugDiscovery #CancerResearch #ScientificResearch #PDCs

Click the link below for the final video summary for this series (watch out for more later!) describing some of our work with Patient Derived Cells (PDCs). If this doesn’t give enough detail, then please reach out to any of our commercial team, Andrew Carnegie Mark Eccleston and Gareth Griffiths to discuss scientific and commercial details for your projects. #cancerresearch #innovation #inaphaea